Which statement about Rasagiline is true?

Prepare for the EDAPT Intracranial Regulation Test with interactive flashcards and multiple choice questions. Each question is accompanied by helpful hints and explanations to boost your readiness. Get started today and ensure your success!

Multiple Choice

Which statement about Rasagiline is true?

Explanation:
Rasagiline increases dopaminergic activity by blocking the enzyme monoamine oxidase B in the brain, reducing dopamine breakdown and raising its availability. This makes Rasagiline an MAOI, specifically an MAO-B inhibitor, used in Parkinson’s disease as initial therapy or as an add-on to levodopa to improve motor symptoms. It isn’t a direct-acting dopamine receptor agonist (that would stimulate receptors directly), nor a dopamine precursor (like levodopa), nor a catecholamine blocker.

Rasagiline increases dopaminergic activity by blocking the enzyme monoamine oxidase B in the brain, reducing dopamine breakdown and raising its availability. This makes Rasagiline an MAOI, specifically an MAO-B inhibitor, used in Parkinson’s disease as initial therapy or as an add-on to levodopa to improve motor symptoms. It isn’t a direct-acting dopamine receptor agonist (that would stimulate receptors directly), nor a dopamine precursor (like levodopa), nor a catecholamine blocker.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy